✦ LIBER ✦

Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer

✍ Scribed by Mark S. Soloway; Melinda Ikard; Kimball Ford

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 425 KB
Volume: 47
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19810201)47:3<476::aid-cncr2820470309>3.0.co;2-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Doxorubicin, vincristine, and cis-diammi

Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer

✍ Trump, Donald L. ;Ettinger, David S. ;Abeloff, Martin D. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

## Abstract Preliminary data suggesting synergistic activity of cisplatinum and doxorubicin and the expected poor prognosis of women with breast cancer who progress on treatment with cyclophosphamide, methotrexate and 5‐fluorouracil (CMF), led to a trial of monthly doxorubicin (50 mg/M^2^), vincris

Concomitant radiation therapy and cis-di

Concomitant radiation therapy and cis-diamminedichloroplatinum (II) in patients with advanced head and neck cancer

✍ Creagan, Edward T. ;Fountain, Karen S. ;Frytak, Stephen ;Desanto, Lawrence W. ;E 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 1 views

## Abstract Three patients with locally advanced head and neck squamous cell cancer received concomitant radiation therapy (XRT) and cis‐diamminedichloroplatinum (CDDP). The dose of 6,000 rads was to be administered in two 3,000‐rad courses separated by 3 weeks. The CDDP, 30 mg/m^2^, was to be give

Cis-diamminedichloroplatinum (II): Secon

Cis-diamminedichloroplatinum (II): Second line induction chemotherapy in advanced ovarian adenocarcinoma

✍ M. Steven Piver; Joseph J. Barlow; Shashikant B. Lele; John H. Malfetano; Mary E 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB

Twenty-one evaluable patients received second-line chemotherapy for recurrent ovarian adenocarcinoma with induction Cisplatin given weekly followed by monthly combination chemotherapy. Forty-two percent of the patients responded to induction weekly Cisplatin. Of the responders, 77% are alive as comp

Cyclophosphamide, adriamycin, and cis-di

Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of patients with advanced head and neck cancer

✍ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 2 views

Chemotherapy of advanced head and neck c

Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis-diamminedichloroplatinum II in an effective outpatient schedule

✍ Steven E. Vogl; Barry H. Kaplan 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 2 views

Mitomycin-C, methotrexate, bleomycin and

Mitomycin-C, methotrexate, bleomycin and cis-diamminedichloroplatinum II in the chemotherapy of advanced squamous cancer of the head and neck

✍ Steven E. Vogl; Harvey Lerner; Barry H. Kaplan; Fernando Camacho; James Cinberg; 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 2 views